Cargando…
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study
PURPOSE: Determine whether specific CTNNB1 or APC mutations in patients with desmoid tumor were associated with differences in clinical responses to systemic treatments. EXPERIMENTAL DESIGN: We established a multi-institutional dataset of previously treated patients with desmoid tumor across four U....
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475245/ https://www.ncbi.nlm.nih.gov/pubmed/35180772 http://dx.doi.org/10.1158/1078-0432.CCR-21-4504 |
_version_ | 1784789870959394816 |
---|---|
author | Nathenson, Michael J. Hu, Junxiao Ratan, Ravin Somaiah, Neeta Hsu, Robert DeMaria, Peter J. Catoe, Heath W. Pang, Angela Subhawong, Ty K. Amini, Behrang Sweet, Kevin Feister, Katharina Malik, Karan Jagannathan, Jyothi Braschi-Amirfarzan, Marta Sheren, Jamie Caldas, Yupanqui Moreno Tellez, Cristiam Rosenberg, Andrew E. Lazar, Alexander J. Maki, Robert G. Benedetto, Pasquale Cohen, Jonathan Trent, Jonathan C. Ravi, Vinod Patel, Shreyaskumar Wilky, Breelyn A. |
author_facet | Nathenson, Michael J. Hu, Junxiao Ratan, Ravin Somaiah, Neeta Hsu, Robert DeMaria, Peter J. Catoe, Heath W. Pang, Angela Subhawong, Ty K. Amini, Behrang Sweet, Kevin Feister, Katharina Malik, Karan Jagannathan, Jyothi Braschi-Amirfarzan, Marta Sheren, Jamie Caldas, Yupanqui Moreno Tellez, Cristiam Rosenberg, Andrew E. Lazar, Alexander J. Maki, Robert G. Benedetto, Pasquale Cohen, Jonathan Trent, Jonathan C. Ravi, Vinod Patel, Shreyaskumar Wilky, Breelyn A. |
author_sort | Nathenson, Michael J. |
collection | PubMed |
description | PURPOSE: Determine whether specific CTNNB1 or APC mutations in patients with desmoid tumor were associated with differences in clinical responses to systemic treatments. EXPERIMENTAL DESIGN: We established a multi-institutional dataset of previously treated patients with desmoid tumor across four U.S. sarcoma centers, including demographic and clinicopathologic characteristics, treatment regimens, and clinical and radiographic responses. CTNNB1 or APC mutation status was determined from prior pathology records, or archival tissue was requested and analyzed by Sanger sequencing and/or next-generation sequencing. Evaluable patients with mutation results were analyzed to determine clinical progression-free survival (cPFS), RECIST 1.1 PFS (rPFS), time to next treatment (TTNT), and overall survival (OS). Kaplan–Meier analysis and Cox proportional hazards regression were performed to identify differences in cPFS, rPFS, TTNT, and OS by mutation subtype, desmoid tumor location, and treatment regimen. RESULTS: A total of 259 evaluable patients were analyzed for at least one of the survival outcomes, with 177 patients having mutation data. First- and second-line cPFS, rPFS, and TTNT were not significantly affected by mutation subtype; however, APC-mutant desmoid tumors demonstrated nonstatistically significant inferior outcomes. Extremity/trunk desmoid tumor location and treatment with doxorubicin-based, methotrexate/vinca alkaloids and sorafenib regimens were associated with better clinical outcomes compared with surgery or “other” therapies, including estrogen-receptor blockade and imatinib. OS was significantly worse with APC or CTNNB1 negative/other mutations. CONCLUSIONS: Mutation subtype did not affect responses to specific systemic therapies. APC mutations and nonextremity desmoid tumor locations remain prognostic for worse outcomes, and earlier initiation of systemic therapy for these higher-risk desmoid tumors should be prospectively evaluated. See related commentary by Greene and Van Tine, p. 3911 |
format | Online Article Text |
id | pubmed-9475245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-94752452023-01-05 Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study Nathenson, Michael J. Hu, Junxiao Ratan, Ravin Somaiah, Neeta Hsu, Robert DeMaria, Peter J. Catoe, Heath W. Pang, Angela Subhawong, Ty K. Amini, Behrang Sweet, Kevin Feister, Katharina Malik, Karan Jagannathan, Jyothi Braschi-Amirfarzan, Marta Sheren, Jamie Caldas, Yupanqui Moreno Tellez, Cristiam Rosenberg, Andrew E. Lazar, Alexander J. Maki, Robert G. Benedetto, Pasquale Cohen, Jonathan Trent, Jonathan C. Ravi, Vinod Patel, Shreyaskumar Wilky, Breelyn A. Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: Determine whether specific CTNNB1 or APC mutations in patients with desmoid tumor were associated with differences in clinical responses to systemic treatments. EXPERIMENTAL DESIGN: We established a multi-institutional dataset of previously treated patients with desmoid tumor across four U.S. sarcoma centers, including demographic and clinicopathologic characteristics, treatment regimens, and clinical and radiographic responses. CTNNB1 or APC mutation status was determined from prior pathology records, or archival tissue was requested and analyzed by Sanger sequencing and/or next-generation sequencing. Evaluable patients with mutation results were analyzed to determine clinical progression-free survival (cPFS), RECIST 1.1 PFS (rPFS), time to next treatment (TTNT), and overall survival (OS). Kaplan–Meier analysis and Cox proportional hazards regression were performed to identify differences in cPFS, rPFS, TTNT, and OS by mutation subtype, desmoid tumor location, and treatment regimen. RESULTS: A total of 259 evaluable patients were analyzed for at least one of the survival outcomes, with 177 patients having mutation data. First- and second-line cPFS, rPFS, and TTNT were not significantly affected by mutation subtype; however, APC-mutant desmoid tumors demonstrated nonstatistically significant inferior outcomes. Extremity/trunk desmoid tumor location and treatment with doxorubicin-based, methotrexate/vinca alkaloids and sorafenib regimens were associated with better clinical outcomes compared with surgery or “other” therapies, including estrogen-receptor blockade and imatinib. OS was significantly worse with APC or CTNNB1 negative/other mutations. CONCLUSIONS: Mutation subtype did not affect responses to specific systemic therapies. APC mutations and nonextremity desmoid tumor locations remain prognostic for worse outcomes, and earlier initiation of systemic therapy for these higher-risk desmoid tumors should be prospectively evaluated. See related commentary by Greene and Van Tine, p. 3911 American Association for Cancer Research 2022-09-15 2022-02-18 /pmc/articles/PMC9475245/ /pubmed/35180772 http://dx.doi.org/10.1158/1078-0432.CCR-21-4504 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Translational Cancer Mechanisms and Therapy Nathenson, Michael J. Hu, Junxiao Ratan, Ravin Somaiah, Neeta Hsu, Robert DeMaria, Peter J. Catoe, Heath W. Pang, Angela Subhawong, Ty K. Amini, Behrang Sweet, Kevin Feister, Katharina Malik, Karan Jagannathan, Jyothi Braschi-Amirfarzan, Marta Sheren, Jamie Caldas, Yupanqui Moreno Tellez, Cristiam Rosenberg, Andrew E. Lazar, Alexander J. Maki, Robert G. Benedetto, Pasquale Cohen, Jonathan Trent, Jonathan C. Ravi, Vinod Patel, Shreyaskumar Wilky, Breelyn A. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study |
title | Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study |
title_full | Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study |
title_fullStr | Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study |
title_full_unstemmed | Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study |
title_short | Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study |
title_sort | systemic chemotherapies retain antitumor activity in desmoid tumors independent of specific mutations in ctnnb1 or apc: a multi-institutional retrospective study |
topic | Translational Cancer Mechanisms and Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475245/ https://www.ncbi.nlm.nih.gov/pubmed/35180772 http://dx.doi.org/10.1158/1078-0432.CCR-21-4504 |
work_keys_str_mv | AT nathensonmichaelj systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT hujunxiao systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT ratanravin systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT somaiahneeta systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT hsurobert systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT demariapeterj systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT catoeheathw systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT pangangela systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT subhawongtyk systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT aminibehrang systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT sweetkevin systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT feisterkatharina systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT malikkaran systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT jagannathanjyothi systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT braschiamirfarzanmarta systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT sherenjamie systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT caldasyupanqui systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT morenotellezcristiam systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT rosenbergandrewe systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT lazaralexanderj systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT makirobertg systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT benedettopasquale systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT cohenjonathan systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT trentjonathanc systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT ravivinod systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT patelshreyaskumar systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy AT wilkybreelyna systemicchemotherapiesretainantitumoractivityindesmoidtumorsindependentofspecificmutationsinctnnb1orapcamultiinstitutionalretrospectivestudy |